Sarepta Therapeutics (SRPT) reported $2.2B in revenue for fiscal 2025, +15.6% year on year. That ranks #1288 by revenue among 2853 SEC filers and #116 in Healthcare. It posted a net loss of −$713M for the same year. Revenue has grown 63.6% a year on average since 2014 ($9.8M then). The fiscal 2025 balance sheet shows $3.3B in total assets, $801M in cash and $829M in long-term debt.
Key figures
| Key figures | FY2025 | YoY | Source |
|---|---|---|---|
| RevenueRevenues | $2.2B | +15.6% | FY20252025-12-31 |
| Gross profit | Not reported | — | |
| Operating incomeOperatingIncomeLoss | −$700M | −$918M | FY20252025-12-31 |
| Net incomeNetIncomeLoss | −$713M | −$949M | FY20252025-12-31 |
| Operating cash flowNetCashProvidedByUsedInOperatingActivities | −$205M | +$308,000 | FY20252025-12-31 |
| Capital expenditurePaymentsToAcquirePropertyPlantAndEquipment | $102M | −25.5% | FY20252025-12-31 |
| Total assetsAssets | $3.3B | −15.5% | FY20252025-12-31 |
| Shareholders' equityStockholdersEquity | $1.1B | −25.3% | FY20252025-12-31 |
| CashCashAndCashEquivalentsAtCarryingValue | $801M | −27.4% | FY20252025-12-31 |
| Long-term debtLongTermDebt | $829M | −27.1% | FY20252025-12-31 |
Revenue is total net sales for the fiscal year, taken from each company's own annual filing.
Reported since the last full year
Three-month figures this company has filed since FY2025. A quarter is not comparable with a full year, and these figures are used nowhere else on the site: not in any ranking, not in comparisons, not in the download.
| Quarter | Revenue | Net income | Source |
|---|---|---|---|
| Q1 20262026-03-31 | $731M | $331M | Open → |
| Q2 20262026-06-30 | $401M | −$4.9M | Open → |
Only periods that end on a calendar quarter appear here. A company whose fiscal year ends in June files on a different calendar, so it has no row.
Where this sits in its sector
Each bar is the spread of the whole sector: the box covers the middle half of companies, the line inside it the median, and the triangle this company. The axis is clipped at the 5th and 95th percentile so a single outlier does not flatten it.
| Where this sits in its sector | FY2025 | Position in sector |
|---|---|---|
| Net marginRank 153 of 161 companies compared | −32.5% | |
| Operating marginRank 154 of 160 companies compared | −31.8% | |
| R&D as share of revenueRank 3 of 102 companies compared | 69.2% | |
| Cash as share of revenueRank 18 of 160 companies compared | 36.5% |
All four are ratios derived from two reported lines, not single filing items. Peer group: companies in the same sector with revenue of $1bn or more; loss-making companies are included.
Profile
- Legal name
- Sarepta Therapeutics, Inc.
- Ticker
- SRPT
- Exchange
- Nasdaq
- SIC classification
- Pharmaceutical Preparations (2834)
- Fiscal year end
- 12-31
- CIK
- 0000873303
Filings
- 10-QAug 5, 2026Open filing →
- 10-QMay 6, 2026Open filing →
- 10-KMar 2, 2026Open filing →
Similar in size, same sector
| Company | Revenue | Net income |
|---|---|---|
| NateraNTRA | $2.3B | −$208M |
| EnovisENOV | $2.2B | −$1.2B |
| Icu MedicalICUI | $2.2B | $732,000 |
| Sarepta TherapeuticsSRPT | $2.2B | −$713M |
| Concentra Group Holdings ParentCON | $2.2B | $166M |
| Privia HealthPRVA | $2.1B | $22.9M |
| QiagenQGEN | $2.1B | $425M |
Cite this page
Ready-made references for the figures on this page, as published on September 25, 2026.
Wikipedia
{{cite web |title=Sarepta Therapeutics — Key figures |url=https://companiesranked.com/en/company/sarepta-therapeutics |website=CompaniesRanked |date=2026-09-25 |language=en}}APA 7
CompaniesRanked. (September 25, 2026). Sarepta Therapeutics — Key figures. CompaniesRanked. https://companiesranked.com/en/company/sarepta-therapeuticsBibTeX
@misc{companiesranked-en-company-sarepta-therapeutics-2026,
author = {{CompaniesRanked}},
title = {{Sarepta Therapeutics — Key figures}},
year = {2026},
howpublished = {\url{https://companiesranked.com/en/company/sarepta-therapeutics}},
note = {Compiled from SEC EDGAR XBRL filings; data as of 2026-09-25},
urldate = {2026-09-25}
}The filing itself
The numbers above are read from this document: 10-K · 0001193125-26-084144 · March 2, 2026
{{cite web |title=Sarepta Therapeutics — Key figures — 10-K (0001193125-26-084144) |url=https://www.sec.gov/Archives/edgar/data/873303/000119312526084144/srpt-20251231.htm |website=SEC EDGAR |publisher=U.S. Securities and Exchange Commission |date=2026-03-02}}The figures are rebuilt with every data refresh, so the reference carries the publication date. Add your own access date if your style requires one.